E

Enlivex Therapeutics (Nasdaq: ENLV)

54 employees

Enlivex is a clinical-stage macrophage reprogramming immunotherapy company that targets diseased macrophages in patients with sepsis.

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Health Care
Therapeutics
Medical

Date founded

2005

Funding rounds raised

Total raised

$10M

from 2 investors over 2 rounds

E

Enlivex Therapeutics (Nasdaq: ENLV) raised $10M on April 23, 2018

Investors: Korea Investment Partners

E

Enlivex Therapeutics (Nasdaq: ENLV) raised $8M on September 19, 2017

Investors: Korea Investment Partners

FAQ